What is the optimal antithrombotic strategy in primary percutaneous coronary intervention?

Current Opinion in Cardiology

Volumn 27, Issue 4, 2012, Pages 361-367

  Sergie, Ziad ^a   Mehran, Roxana ^a,b   Stone, Gregg W ^b,c  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b CARDIOVASCULAR RESEARCH FOUNDATION   (United States)

^c Howard Hughes Medical Institute   (United States)

Author keywords

acute coronary syndrome; bivalirudin; percutaneous coronary intervention; ST segment elevation myocardial infarction, thrombin and antithrombin

Indexed keywords

ANTICOAGULANT AGENT; ENOXAPARIN; FIBRINOGEN RECEPTOR ANTAGONIST; FONDAPARINUX; HEPARIN; HIRULOG; LOW MOLECULAR WEIGHT HEPARIN; PURINERGIC P2Y RECEPTOR ANTAGONIST; PURINERGIC P2Y12 RECEPTOR;

ACUTE CORONARY SYNDROME; BLEEDING; CARDIOVASCULAR MORTALITY; CLINICAL TRIAL (TOPIC); HEART INFARCTION; HEART MUSCLE ISCHEMIA; HIGH RISK POPULATION; HUMAN; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PHENOTYPE; PRIORITY JOURNAL; REVIEW; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS; THROMBOCYTOPENIA;

EID: 85027929561     PISSN: 02684705     EISSN: 15317080     Source Type: Journal    
DOI: 10.1097/HCO.0b013e3283540828     Document Type: Review

References (41)

1. Berry JD, Dyer A, Cai X, et al. Lifetime risks of cardiovascular disease. N Engl J Med 2012; 366:321-329.
2. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics -2012 update: A report from the American Heart Association. Circulation 2012; 125:e2-e220.
3. Anderson JL, Adams CD, Antman EM, et al. 2011 ACCF/AHA focused update incorporated into the ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011; 123:e426-e579.
4. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361:1045-1057.
5. Doyle BJ, Rihal CS, Gastineau DA, Holmes DR Jr. Bleeding, blood transfusion, and increased mortality after percutaneous coronary intervention: Implications for contemporary practice. J Am Coll Cardiol 2009; 53:2019-2027.
6. Baber U, Kovacic J, Kini AS, et al. How serious a problem is bleeding in patients with acute coronary syndromes? Curr Cardiol Rep 2011; 13:312-319.
7. Mehran R, Pocock SJ, Nikolsky E, et al. A risk score to predict bleeding in patients with acute coronary syndromes. J Am Coll Cardiol 2010; 55:2556-2566.
8. Quinlan DJ, Eikelboom JW, Goodman SG, et al. Implications of variability in definition and reporting of major bleeding in randomized trials of oral P2Y12 inhibitors for acute coronary syndromes. Eur Heart J 2011; 32:2256-2265.
9. Mehran R, Rao SV, Bhatt DL, et al. Standardized bleeding definitions for cardiovascular clinical trials: A consensus report from the Bleeding Academic Research Consortium. Circulation 2011; 123:2736-2747.
10. Rao SV, Mehran R. Evaluating the bite of BARC. Circulation 2012; 125:1344-1346.
11. Ndrepepa G, Schuster T, Hadamitzky M, et al. Validation of the Bleeding Academic Research Consortium definition of bleeding in patients with coronary artery disease undergoing percutaneous coronary intervention. Circulation 2012; 125:1424-1431.
12. Mehran R, Pocock S, Nikolsky E, et al. Impact of bleeding on mortality after percutaneous coronary intervention results from a patient-level pooled analysis of the REPLACE-2 (randomized evaluation of PCI linking angiomax to reduced clinical events), ACUITY (acute catheterization and urgent intervention triage strategy), and HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trials. JACC Cardiovasc Interv 2011; 4:654-664.
13. Mehran R, Pocock SJ, Stone GW, et al. Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: A risk model from the ACUITY trial. Eur Heart J 2009; 30:1457-1466.
14. Kim YH, Lee JY, Ahn JM, et al. Impact of bleeding on subsequent early and late mortality after drug-eluting stent implantation. JACC Cardiovasc Interv 2011; 4:423-431.
15. White HD. Editorial: Do we need another bleeding definition? What does the Bleeding Academic Research Consortium definition have to offer? Curr Opin Cardiol 2011; 26:275-278.
16. Tricoci P, Huang Z, Held C, et al. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med 2012; 366:20-33.
17. Hamm CW, Bassand JP, Agewall S, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011; 32:2999-3054.
18. Van De Car DA, Rao SV, Ohman EM. Bivalirudin: A review of the pharmacology and clinical application. Expert Rev Cardiovasc Ther 2010; 8:1673-1681.
19. Wong CK, White HD. Antithrombotic therapy in ST-segment elevation myocardial infarction. Expert Opin Pharmacother 2011; 12:213-223.
20. Kimmelstiel C, Zhang P, Kapur NK, et al. Bivalirudin is a dual inhibitor of thrombin and collagen-dependent platelet activation in patients undergoing percutaneous coronary intervention. Circ Cardiovasc Interv 2011; 4:171-179.
21. Stone GW, Witzenbichler B, Guagliumi G, et al. Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): Final 3-year results from a multicentre, randomised controlled trial. Lancet 2011; 377:2193-2204.
22. Stone GW, Witzenbichler B, Guagliumi G, et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 2008; 358:2218-2230.
23. Mehran R, Lansky AJ, Witzenbichler B, et al. Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial. Lancet 2009; 374:1149-1159.
24. Dwivedi G, Steed R, Chong AY. Bivalirudin for patients with ST-elevation myocardial infarction. Lancet 2011; 378:1915-1916.
25. Cortese B, Limbruno U, Severi S, et al. Effect of prolonged bivalirudin infusion on ST-segment resolution following primary percutaneous coronary intervention (from the PROBI VIRI 2 study). Am J Cardiol 2011; 108:1220-1224.
26. Hakim DA, Dangas GD, Caixeta A, et al. Impact of baseline thrombocytopenia on the early and late outcomes after ST-elevation myocardial infarction treated with primary angioplasty: Analysis from the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONSAMI) trial. Am Heart J 2011; 161:391-396.
27. Suh JW, Mehran R, Claessen BE, et al. Impact of in-hospital major bleeding on late clinical outcomes after primary percutaneous coronary intervention in acute myocardial infarction the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial. J Am Coll Cardiol 2011; 58:1750-1756.
28. Verheugt FW, Steinhubl SR, Hamon M, et al. Incidence, prognostic impact, and influence of antithrombotic therapy on access and nonaccess site bleeding in percutaneous coronary intervention. JACC Cardiovasc Interv 2011; 4:191-197.
29. Brener SJ, Mehran R, Dressler O, et al. Diabetes mellitus, myocardial reperfusion, and outcome in patients with acute ST-elevation myocardial infarction treated with primary angioplasty (from HORIZONS AMI). Am J Cardiol 2012; 109:1111-1116.
30. Witzenbichler B, Mehran R, Guagliumi G, et al. Impact of diabetes mellitus on the safety and effectiveness of bivalirudin in patients with acute myocardial infarction undergoing primary angioplasty: Analysis from the HORIZONS-AMI (Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction) trial. JACC Cardiovasc Interv 2011; 4:760-768.
31. Hanna EB, Chen AY, Roe MT, et al. Characteristics and in-hospital outcomes of patients with non-ST-segment elevation myocardial infarction and chronic kidney disease undergoing percutaneous coronary intervention. JACC Cardiovasc Interv 2011; 4:1002-1008.
32. Saltzman AJ, Stone GW, Claessen BE, et al. Long-term impact of chronic kidney disease in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention: The HORIZONSAMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial. JACC Cardiovasc Interv 2011; 4:1011-1019.
33. Kastrati A, Neumann FJ, Schulz S, et al. Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction. N Engl J Med 2011; 365:1980-1989.
34. Caixeta A, Dangas GD, Mehran R, et al. Incidence and clinical consequences of acquired thrombocytopenia after antithrombotic therapies in patients with acute coronary syndromes: Results from the Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial. Am Heart J 2011; 161:298e1-306e1.
35. Montalescot G, Zeymer U, Silvain J, et al. Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: The international randomised open-label ATOLL trial. Lancet 2011; 378:693-703.
36. Kadakia MB, DesaiNR, Alexander KP, et al.Useof anticoagulant agents and risk of bleeding among patients admitted with myocardial infarction: A report from the NCDR ACTION Registry - GWTG (National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network Registry - Get With the Guidelines). JACC Cardiovasc Interv 2010; 3:1166-1177.
37. Dangas GD, Mehran R, Nikolsky E, et al. Effect of switching antithrombin agents for primary angioplasty in acute myocardial infarction: The HORIZONSSWITCH analysis. J Am Coll Cardiol 2011; 57:2309-2316.
38. Dangas GD, Caixeta A, Mehran R, et al. Frequency and predictors of stent thrombosis after percutaneous coronary intervention in acute myocardial infarction. Circulation 2011; 123:1745-1756.
39. Stone GW. Bivalirudin in acute myocardial infarction: NICE guidance. Heart 2012; 98:435-437.
40. Kessler DP, Kroch E, Hlatky MA. The effect of bivalirudin on costs and outcomes of treatment of ST-segment elevation myocardial infarction. Am Heart J 2011; 162:494e2-500e2.
41. Pinto DS, Ogbonnaya A, Sherman SA, et al. Bivalirudin therapy is associated with improved clinical and economic outcomes in ST-elevation myocardial infarction patients undergoing percutaneous coronary intervention: Results from an observational database. Circ Cardiovasc Qual Outcomes 2012; 5:52-61.